Targeting angiogenesis for the treatment of advanced melanoma

Oncology Reviews 09/2011; 5(3):167-176. DOI: 10.1007/s12156-011-0075-2

ABSTRACT Metastatic melanoma (MM) carries a dismal prognosis, as it is largely resistant to conventional chemotherapy, bio-chemotherapy
and immunotherapy. The search for new effective treatments is an unquestionable priority in MM. A wealth of novel therapies
have been currently tested in oncology and MM represents an attractive model for investigation. The process of angiogenesis
is crucial for the establishment and progression of most solid tumors including melanoma. As the mechanisms of angiogenesis
are being elucidated, strategies against angiogenic targets are among the most innovative in oncology drug development. Multiple
growth factors secreted in melanoma trigger angiogenic responses and a variety of receptors are activated. Many of these function
in synergy with the extracellular matrix, setting in motion downstream pathways. It is unlikely, therefore, that targeting
a single angiogenic axis will be sufficient to achieve tumor control in melanoma, as exemplified by several negative trials
conducted to date. Current anti-angiogenic strategies include those targeting pro-angiogenic ligands (bevacizumab, VEGF-Trap:
aflibercept), kinases associated with cell surface receptors and growth factor pathways (sorafenib, axitinib, erlotinib, imatinib),
matrix metalloproteinases (MMPs), intergrins [batimastat, marimastat, etaracizomab (abegrin)] and potentially mTOR inhibitors
(everolimus). Many of those recently developed compounds targeting key angiogenic pathways are in the final clinical trial
stages. Future approaches to tackling angiogenesis in MM should take into account therapeutic synergism and drug resistance,
by combining novel agents with different mechanisms of action against different angiogenic pathways. In this review, we focus
primarily on current anti-angiogenic strategies in melanoma, with a view to future developments.

KeywordsMelanoma–Angiogenesis–Growth factors–VEGF inhibitors

1 Bookmark
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Cutaneous melanoma is a highly invasive and metastatic tumor. Degradation of basement membranes and extracellular matrix is an essential step in melanoma cell migration, invasion, and metastasis formation. Matrix metalloproteinases and their tissue inhibitors play a crucial role in these complex multistep processes. Melanoma cells may express a number of matrix metalloproteinase family members (MMP-1, MMP-2, MMP-9, MMP-13, and MT1-MMP) as well as their tissue inhibitors (TIMP-1, TIMP-2, and TIMP-3). Numerous studies have examined matrix metalloproteinases, their tissue inhibitors, and the molecules that regulate their expression and/or activation in melanoma cell lines in vitro and in vivo, and in human melanocytic lesions. Recent results have indicated that adhesion molecules such as CD44 and integrin alphavbeta3 are involved in positioning activated matrix metalloproteinase molecules on the cell surface of invasive tumor cells. In this review we evaluate these novel aspects of the role of matrix metalloproteinases and their tissue inhibitors in melanoma progression. We conclude that the balance between levels of activated matrix metalloproteinases and expression levels of their tissue inhibitors, and the coexpression of activated matrix metalloproteinases and adhesion molecules are important factors in determining melanoma cell invasion, tumor growth, and metastasis formation.
    Journal of Investigative Dermatology 10/2000; 115(3):337-44. · 6.19 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: This phase III, randomized, double-blind, placebo-controlled study was conducted to evaluate the efficacy and safety of sorafenib with carboplatin and paclitaxel (CP) in patients with advanced melanoma who had progressed on a dacarbazine- or temozolomide-containing regimen. A total of 270 patients were randomly assigned to receive intravenous paclitaxel 225 mg/m2 plus intravenous carboplatin at area under curve 6 (AUC 6) on day 1 of a 21-day cycle followed by either placebo (n = 135) or oral sorafenib 400 mg (n = 135) twice daily on days 2 to 19. The primary efficacy end point was progression-free survival (PFS); secondary and tertiary end points included overall survival and incidence of best response, respectively. The median PFS was 17.9 weeks for the placebo plus CP arm and 17.4 weeks for the sorafenib plus CP arm (hazard ratio, 0.91; 99% CI, 0.63 to 1.31; two-sided log-rank test P = .49). Response rate was 11% with placebo versus 12% with sorafenib. Dermatologic events, grade 3 thrombocytopenia, diarrhea, and fatigue were more common in patients treated with sorafenib plus CP versus placebo plus CP. In this study, the addition of sorafenib to CP did not improve any of the end points over placebo plus CP and cannot be recommended in the second-line setting for patients with advanced melanoma. Both regimens had clinically acceptable toxicity profiles with no unexpected adverse events. A trial of similar design for the first-line treatment of patients with advanced melanoma (intergroup trial E2603) is currently ongoing.
    Journal of Clinical Oncology 05/2009; 27(17):2823-30. · 18.04 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Vascular endothelial growth factor (VEGF) is a proangiogenic molecule produced by melanoma cells. We hypothesized that administration of bevacizumab (Bev), a monoclonal antibody that neutralizes VEGF, with low-dose interferon alfa-2b (IFN-alpha2b), an inhibitor of basic fibroblast growth factor (FGF), would lead to the regression of metastatic melanoma. Patients with metastatic melanoma were randomized to receive Bev (15 mg/kg intravenously every 2 weeks) with or without low-dose IFN-alpha2b (1 MU/m2 subcutaneously daily). Patients exhibiting a clinical response or stable disease after 12 weeks were treated until disease progression. Thirty-two patients (16 per arm) were accrued (18 male, 14 female; mean age 57.5 years). Both regimens were well tolerated. Six patients developed easily managed exacerbations of preexisting hypertension. Two patients developed grade 3 proteinuria that resolved after a treatment break. IFN-alpha2b therapy was associated with grade 1 to 2 constitutional symptoms. Arterial thromboembolic complications were observed in three patients (two mild myocardial infarctions, one transient ischemic attack), all of whom had risk factors. One patient (Bev plus IFN-alpha2b arm) had locally recurrent scalp disease that partially responded to therapy. Eight patients (five Bev, three Bev plus IFN-alpha2b) had prolonged disease stabilization (24 to 146 weeks). Plasma levels of VEGF and FGF did not correlate with any clinical parameter. The patient with the longest period of stable disease had the highest baseline VEGF and FGF. Bev was well tolerated at this dose and prolonged disease stabilization was achieved in one-quarter of metastatic melanoma patients. Low-dose IFN-alpha2b did not augment the activity of Bev.
    Annals of Surgical Oncology 09/2007; 14(8):2367-76. · 4.12 Impact Factor